The next quantum leap forward? Bimekizumab for psoriasis

Affiliations

¹ Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC 27157-1071, USA.
² Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC 27157-1071, USA. Electronic address: sfeldman@wakehealth.edu.

Comment

William W Huang et al. Lancet. 2021.

. 2021 Feb 6;397(10273):446-448.

doi: 10.1016/S0140-6736(21)00269-5.

¹ Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC 27157-1071, USA.
² Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC 27157-1071, USA. Electronic address: sfeldman@wakehealth.edu.

No abstract available

Comment on

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, Blauvelt A. Gordon KB, et al. Lancet. 2021 Feb 6;397(10273):475-486. doi: 10.1016/S0140-6736(21)00126-4. Lancet. 2021. PMID: 33549192 Clinical Trial.
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, Gordon KB, Merola JF, Okubo Y, Madden C, Wang M, Cioffi C, Vanvoorden V, Lebwohl M. Reich K, et al. Lancet. 2021 Feb 6;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2. Lancet. 2021. PMID: 33549193 Clinical Trial.